Figure S19 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Figure S19. (A) UMAP embedding of single cell transcriptomes of all macrophages obtained from all samples in this trial. Labeled are granular macrophage subsets separated by tumor v.s. normal tissue, and by timepoint. (B) UMAP embeddings showing marker gene expression for macrophage subsets in (A). (C) Relative M1 macrophage proportion in fast and slow progressing patients separated by timepoint. (D) Macrophage subtype proportions at baseline and FU1 in fast versus slow progressing patients, and in non-responder and responder patients. (E) Relative M1 macrophage proportion in non-responder and responder patients separated by timepoint. (F) Proportion of SPP1+ macrophages in nonresponder and responder patients split by timepoint. Statistical comparisons performed using a Wilcoxon signed-rank test. (G) Change in relative M1 proportion from BL to FU1 plotted against change in tumor volume after 1 cycle of chemotherapy, segregated by non-responder and responder patients. (H) GSVA performed for M2 signatures on bulk RNA-seq samples split by timepoints and progression status.